Increased demand for diabetes testing is a challenge for clinical
The Atellica® CH Enzymatic Hemoglobin A1c
(A1c_E) Assay 1 is an easy-to-implement
chemistry test, offering precise and accurate results for diabetic
The A1c_E assay is less prone to testing interference3
and greatly improves laboratory throughput compared to traditional
TARRYTOWN, N.Y.–(BUSINESS WIRE)–Siemens Healthineers announced today the global availability of its new
Atellica CH Enzymatic Hemoglobin A1c (A1c_E) Assay to assist clinicians
in diagnosing and monitoring diabetes, a growing and potentially deadly
The International Diabetes Federation projects 642 million people
worldwide will have diabetes by 2040 because of leading factors such as
higher levels of urbanization, aging populations, and the growing
adoption of more sedentary lifestyles which leads to insufficient
physical activity, greater rates of obesity and a higher intake of
unhealthy foods.4 When diagnosed, treated and monitored
regularly, diabetes is manageable and, in some cases, reversible. Left
untreated, however, blood sugar can rise to dangerous levels and lead to
kidney damage and other irreversible health consequences.
As diabetes awareness increases and screening for the chronic disease
rises, testing options for the clinical laboratory are evolving both in
sophistication and practicality. The Siemens Healthineers Atellica CH
Enzymatic Hemoglobin A1c meets new standards of testing and offers
laboratories improved performance—both precision and accuracy2—over
leading alternative methodologies.
“Demands for screening and monitoring on the laboratory will continue to
grow as the diabetic population continues to expand,” said Deepak Nath,
PhD, President of Laboratory Diagnostics, Siemens Healthineers.
“Instruments with higher throughput capabilities offer laboratories the
ability to run a greater volume of tests and produce patient results
more quickly, thus improving patient satisfaction. Laboratories are
seeking HbA1c assays that can be integrated onto chemistry testing
platforms and that provide the accurate and precise results patients
deserve. The new Atellica CH Enzymatic Hemoglobin A1c Assay offers these
Siemens Healthineers offers a variety of HbA1c assays for diabetes
testing on its clinical laboratory and point-of-care solutions,
including the Atellica® CH Analyzer, ADVIA®
Chemistry Systems, Dimension® Systems, Dimension Vista®
Systems, and the DCA Vantage® Analyzer.
For further information on the Atellica CH A1c_E Assay, please see: http://siemens-healthineers.com/atellica-hba1c
|1||Product availability varies by country.|
Atellica CH A1c_E IFU. Siemens Healthcare Diagnostics Inc.
11111609_EN Rev. 01, 2019-01
The Atellica CH A1c_E assay is NGSP certified and an
IFCC-standardized HbA1c assay that demonstrates < 5% change with most known Hb variants (HbC, HbD, HbE, HbS, and HbA2).
International Diabetes Federation. IDF Diabetes Atlas, 8th edn.
Siemens Healthineers enables healthcare providers worldwide to
increase value by empowering them on their journey towards expanding
precision medicine, transforming care delivery, improving patient
experience and digitalizing healthcare. A leader in medical technology,
Siemens Healthineers is constantly innovating its portfolio of products
and services in its core areas of diagnostic and therapeutic imaging and
in laboratory diagnostics and molecular medicine. Siemens Healthineers
is also actively developing its digital health services and enterprise
services. In fiscal 2018, which ended on September 30, 2018, Siemens
Healthineers generated revenue of €13.4 billion and adjusted profit of
€2.3 billion and has about 50,000 employees worldwide. Further
information is available at www.siemens-healthineers.com.
Kimberly Nissen, Siemens Healthineers
+1 610 448-6355; Email: [email protected]